BioFocus has achieved a development milestone under its medicinal chemistry services agreement with UCB for the discovery and development of next generation treatments for severe diseases. BioFocus has received an undisclosed milestone payment related to the candidate selection stage.
“This milestone payment from UCB demonstrates BioFocus’ ability to support its client projects through to success,” said Chris Newton, senior vice president, Galapagos Services. “This innovative collaboration allows UCB to progress their program externally while applying the specific project expertise that UCB had already built internally.”
Neil Weir, senior vice president of discovery, UCB, and chair of the Innovation Board of the Association of the British Pharmaceutical Industry, said, “We are pleased with BioFocus’ contribution and our achievement in reaching this milestone. Collaborations like this one with BioFocus are a foundation of UCB’s strategy and we believe advances towards new therapies can be accelerated by combining our expertise in discovery science with a wide network.”